Crucial Meetings With EMA Due For Travere/Vifor’s Sparsentan & Minoryx’s Leriglitazone

 
• By Vibha Sharma

Developers of three new drugs, including two orphan medicines, that are nearing the final stages of their EU regulatory review cycle could be asked to explain why the European Medicines Agency should recommend approval of their products.

Conference chair on wood table, black leather chair in meeting room decorated with modern white walls and wooden floor
CHMP oral explanation meetings are typically held towards the end of a product’s regulatory review cycle • Source: Shutterstock

More from Europe

More from Geography